drugset / Trial / NCT07007988

A Phase I Study of SIM0388 in Participants With Malignant Ascites.

NCT07007988

Phase 1 Recruiting 50 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Malignant Ascites is a common complication of malignant tumor. The objective of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of intraperitoneal perfusion with Docetaxel Polymeric Micelles (SIM0388) for injection in patients with malignant ascites

Timeline

Start
2025-04-24
Primary completion
2027-06
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule Other

Indications